was first described by Pindborg in 1955. they occur as intraosseous(94%) and extraosseous variants. Although the prognosis of CEOT was regarded as ameloblastoma in the past, contemporary accumulating data suggest that CEOT have better prognosis than ameloblastoma. But decisive evidences are lacked. Although CEOT is a rare odontogenic tumor, the histopathologic features have so much diversity. Especially interesting aspects are the being of amyloid and Langerhans' cells. Author classify 6 cases of CEOT to scanty, small, and lage as produced amount of amyloid and then perform immunohistochemical study about pancytokertin, cytokeratin8/18, vimentin, CD1a, and VEGF(vascular endothelial growth factor) for verifying the differentiation state of tumor cells and the comparative infiltrative potential with ameloblastoma. Author obtain several conclusion and presumptive facts through this study and previous researchs. Tumor cells of CEOT exhibited different differentiating features as amount of amyloid, presumably tumor cells of CEOT with scanty amount of amyloid represent enamel epithelium-like cells of presecretory stage in amelogenesis, tumor cells of CEOT with small amount of amyloid represent ameloblast-like cells of secretory stage in amelogenesis, and tumor cells of CEOT with large amount of amyloid represent reduced enamel epithelium-like cells after enamel formation. Epithelial-Mesenchymal transition phenomenon developed in tumor cells of CEOT with small amount of amyloid. Inflammatory reaction was not related with being Langerhansʼ cells. Author tentatively concluded that CEOT with Langerhans cells exhibited a tendency of non-calcification, scanty amyloid formation and frequently occurring at the maxillary anterior region through the previous studies and this study. Infiltrative growth potential of CEOT was lower than ameloblastoma regarding only VEGF expression.

I. 서 론
 II. 연구재료 및 방법
  1. 조직표본
  2. 면역조직화학적 염색
  3. 평가방법
 III. 결 과
  1. H&E 염색
  2. 상피세포적 특성과 랑거한스세포의 유무에 대한면역조직화학적 염색
  3. 석회화 상피성 치성종양과 법랑모세포종에서 발현되는 VEGF 양성세포에 대한 비율
 IV. 토 론
 V. 결 론
 VI. 참고문헌

• 박경주(단국대학교 치과대학 구강병리학교실, 구강노화연구소) | Gyeong Ju Park